<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33369">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01789619</url>
  </required_header>
  <id_info>
    <org_study_id>xxx</org_study_id>
    <nct_id>NCT01789619</nct_id>
  </id_info>
  <brief_title>Extended Release Tacrolimus (Advagraf®) in Severe Adult Atopic Dermatitis Patients</brief_title>
  <official_title>Extended Release Tacrolimus (Advagraf®) in Severe Adult Atopic Dermatitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical efficacy of the extended release formulation of tacrolimus
      (Advagraf®) in patients with severe atopic dermatitis, who can not be treated adequately
      with cyclosporine A because of side effects and/or non-responsiveness.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Change in Scoring Atopic Dermatitis (SCORAD)</measure>
    <time_frame>Every 4 weeks up to one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical eczema scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-Oriented Eczema Measure (POEM)</measure>
    <time_frame>Every 4 weeks up to one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Self administered eczema score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Thymus and Activation-Regulated Chemokine in serum (TARC)</measure>
    <time_frame>Every 4 weeks up to one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Biomarker atopic dermatitis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Extended release tacrolimus (Advagraf®)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extended release tacrolimus (Advagraf®)</intervention_name>
    <arm_group_label>Extended release tacrolimus (Advagraf®)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe atopic dermatitis, who can not be treated adequately with Cycloporin
        A because of side effects and/or non-responsiveness.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with severe atopic dermatitis, uncontrolled by topical treatment
             (indication for oral immunosuppressive drugs), who are unresponsive to Cyclosporin A,
             or in which treatment was discontinued because of side effects.

        Exclusion Criteria:

          -  Concomitant use of other oral immunosuppressive drugs and/or UV light therapy

          -  Preexisting abnormalities in liver function, kidney function or haematological
             abnormalities

          -  History of malignancy within the last 5 years

          -  Uncontrolled hypertension

          -  Pregnancy or lactation; wish for pregnancy during the treatment period

          -  Infections requiring continued therapy

          -  Known positivity for HIV

          -  Evidence of drug and/or alcohol abuse
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C AFM Bruijnzeel-Koomen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>M S de Bruin-Weller, MD, PhD</last_name>
    <phone>+31 88 755 7388</phone>
    <phone_ext>-</phone_ext>
    <email>m.s.debruin-weller@umcutrecht.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M S de Bruin-Weller, MD, PhD</last_name>
      <phone>+31 88 755 7388</phone>
      <email>m.s.debruin-weller@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>M S de Bruin-Weller, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>J van der Schaft, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 8, 2013</lastchanged_date>
  <firstreceived_date>February 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Dr M.S. de Bruin-Weller</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
